1. The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P‐glycoprotein. Issue 3 (3rd March 2014) Authors: Groenendaal, Dorien; Strabach, Gregory; Garcia‐Hernandez, Alberto; Kadokura, Takeshi; Heeringa, Marten; Mol, Roelof; Eltink, Charlotte; Onkels, Hartmut Journal: Clinical pharmacology in drug development Issue: Volume 3:Issue 3(2014:May/Jun.) Page Start: 194 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗